scholarly journals Stereotactic Laser Ablation (SLA) followed by consolidation stereotactic radiosurgery (cSRS) as treatment for brain metastasis that recurred locally after initial radiosurgery (BMRS): a multi-institutional experience

Author(s):  
Isabela Peña Pino ◽  
Jun Ma ◽  
Yusuke S. Hori ◽  
Elena Fomchenko ◽  
Kathryn Dusenbery ◽  
...  
Author(s):  
John C Flickinger ◽  
Douglas Kondziolka ◽  
L Dade Lunsford ◽  
Robert J Coffey ◽  
Michael L Goodman ◽  
...  

Cureus ◽  
2012 ◽  
Author(s):  
Aizik L Wolf ◽  
Sachin Batra ◽  
Pietro Bortoletto ◽  
Chetan Bettegowda ◽  
Beatriz E Amendola ◽  
...  

2021 ◽  
Author(s):  
Isabela Peña Pino ◽  
Jun Ma ◽  
Yusuke Hori ◽  
Elena Fomchenko ◽  
Kathryn Dusenbery ◽  
...  

Abstract Introduction: The optimal treatment paradigm for brain metastasis that recurs locally after initial radiosurgery (BMRS) remains an area of active investigation. Here, we report outcomes for patients with BMRS treated with stereotactic laser ablation (SLA, also known as laser interstitial thermal therapy, LITT)followed by consolidation radiosurgery (cSRS). Methods: Clinical outcome of 20 patients with 21histologically confirmed BMRS treated with SLA followed by consolidation SRS and >6 months follow-up were collected retrospectively across three participating institutions. Results: Consolidation SRS (5 Gy x 5 or 6 Gy x 5) wascarried out 16-73 days (median of 26 days) post-SLA of BMRS. There were no new neurological deficits after SLA/cSRS. While 3/21 (14.3%) patients suffered temporary Karnofsky Performance Score (KPS) decline after SLA, no KPS declines was observed after cSRS. There were no 30-day mortalities or wound complications. Two patients required re-admission within 30 days of cSRS (severe headache that resolved with steroid therapy (n=1) and new onset seizure (n=1)). With a median follow-up of 228 days (range: 178-1367 days), the local control rate at 6 and 12 months (LC6, LC12) was 100%. All showed diminished FLAIR volume surrounding the SLA/cSRS treated BMRS at the six-month follow-up; none of the patients required steroid for symptoms attributable to these BMRS. These results compare favorably to the available literature for repeat SRS or SLA-only treatment of BMRS.Conclusions: This multi-institutional experience supports further investigations of SLA/cSRS as a treatment strategyfor BMRS.


2016 ◽  
Vol 18 (suppl_6) ◽  
pp. vi196-vi196
Author(s):  
Clark Chen ◽  
Mir Amaan ◽  
Robert Rennert ◽  
Kate Carroll ◽  
Mayur Sharma ◽  
...  

2020 ◽  
Vol 142 ◽  
pp. 168-174 ◽  
Author(s):  
Emory R. McTyre ◽  
Michael H. Soike ◽  
Michael Farris ◽  
Diandra N. Ayala-Peacock ◽  
Jaroslaw T. Hepel ◽  
...  

2021 ◽  
Vol 61 ◽  
pp. 13
Author(s):  
HA Beydoun ◽  
MA Beydoun ◽  
S Huang ◽  
SM Eid ◽  
AB Zonderman

2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi41-vi41
Author(s):  
Isabela Pena-Pino ◽  
Jun Ma ◽  
Yusuki Hori ◽  
Elena Fomchenko ◽  
Kathryn Dusenbery ◽  
...  

Abstract INTRODUCTION In independent clinical trials, ~30% of brain metastases recur locally after radiosurgery (BMRS). For these lesions, treatment with stereotactic laser ablation (SLA, also known as laser interstitial thermal therapy (LITT)) alone achieves a 12-month local control (LC12) of 54-85% while repeat SRS achieved LC12 of 54-79%. Here, we report favorable outcomes for BMRS treated with SLA followed by consolidation radiosurgery (SLA/cSRS). METHODS Clinical outcome of 18 patients with 19 histologically confirmed BMRS treated with SLA followed by consolidation SRS and >3 months follow-up were collected retrospectively across three institutions. Local control was defined as stability or decrease in contrast-enhancing (CE) and FLAIR volume. RESULTS SLA achieved ablation of 73-100% of the BMRS CE volumes. Consolidation hypo-fractionated radiosurgery (5 Gy x 5 or 6 Gy x 5) was carried out 16-40 days post-SLA (median of 26 days). With a median follow-up of 185 days (range: 93-1367 days) and median overall survival (OS) of 185 days (range: 99-1367 days), 100% LC12 was achieved. 13/18 (72%) patients that required steroid therapy prior to SLA/cSRS were successfully weaned off steroid by three months post-SLA/cSRS. Post-SLA, KPS declined for 3/19 (16%) patients and improved for 1/19 (5%) patients. No KPS changes occurred subsequent to consolidation SRS. There were no 30-day mortalities or wound complications. Two patients required re-admission within 30 days of SRS (severe headache that resolved with steroid therapy (n=1) and new-onset seizure (n=1)). Except for two patients who suffered histologically confirmed, local failure at 649 and 899 days, all other patients are either alive (n=6) or died from systemic disease progression (n=10). None of the treated patients developed symptomatic radiation necrosis. CONCLUSIONS This collaborative institutional experience support efficacy and safety of SLA followed by consolidation SRS as a treatment for BMRS. The treatment strategy warrants further investigations.


Sign in / Sign up

Export Citation Format

Share Document